Insulin Detemir and Basal Insulin Therapy

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue SUPPL. 1, 2007, Pages 7-13

  Russell Jones, David L ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; SHORT ACTING DRUG; SULFONYLUREA;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ECONOMIC ASPECT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 34548590840     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(07)80003-X     Document Type: Article

References (50)

1. International Diabetes Federation. Facts and figures (October 19, 2006). http://www.idf.org/home/index.cfm?node=6 Accessed
2. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes (November 28, 2006). http://www.idf.org/home/index.cfm?node=1457 Accessed
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. The Diabetes Control and Complications Trial Research Group. The effect of illtensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
5. Hellman R., and Regan J. Rosen H. Effect of intensive treatment of diabetes of the risk of death or renal failure in NIDDM and IDDM. Diabetes Care 20 (1997) 258-264
6. International Diabetes Federation. Diabetes Atlas. third edition (September 9, 2006). http://www.eatlas.idf.org/media/ www.idl.org
7. American Diabetes Association. Diabetes Statistics (September 26, 2006). http://www.diabetes.org/diabetes-statisticsdsp Available at:
8. Nathan D., Lachin J., and Cleary R. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003) 2294-2303
9. Nathan D., Cleary P., Backlund J.-Y., et al. Intensive diabetes treament and cm:diovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
10. Stratton I., Adler A., Nell H., et al. Association of glycaemia with macl:ovascular and microvascular complications of type 2 diabete (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
11. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
12. American Association of Clinical Endocrinologists. American College of Endocrinology consensus statement on guidelines for glycemic control. Available at:. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf Accessed September 26, 2006
13. Rohlfing C., Wiedmeyer H.-M., Little R., et al. Defining the relationship between plasma glucose and HbAlc: analysis of glucose profiles and HbA 1 c in the Diabetes Control and Complication s Trial. Diabetes Care 25 (2002) 275-278
14. State of Diabetes in America™ Report. Available at:. http://www.maae.com/public/awarcness/stateofdiabetes/DiabetesAmericaRepo rt.pdf Accessed September 26, 2006
15. Gough S., Frandsen K., and Toft A. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study. 66th Annual Scientific Sessions of the American Diabetes Association (June 9-13, 2006) Washington, DC
16. American Diabetes Association. Postprandial blood glucose. Diabetes Care 24 (2001) 775-778
17. Nathan D., Buse J., Davidson M., et al. Management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
18. ACE/AACE Diabetes Road Map Task Force. Road map for the prevention and treatment of type 2 diabetes. Available at:. http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf Accessed September 26, 2006
19. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes 28 Suppl 2 (2004) S23-S28
20. Owens D., Coates P., Luzio S., et al. Pharmacoldnetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous rejection sites. Diabetes Care 23 (2000) 813-819
21. Levemir®. insulin detemir [rDNA origin] injection (2005), Novo Nordisk A/S, Bagsvaerd, Demnark [prescribing information]
22. Kurtzhals R., Havelund S., Jonassen J., and Markussen J. Effect of fatty adds and selected drugs on the albumin binding of a long-acting, acylated insulin anMogue. J Pharm Sci 86 (1997) 1365-1368
23. Markussen J., Havelund S., and Kurtzhals R. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39 (1996) 281-288
24. Havehmd S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21 (2004) 1498-1504
25. Klein O., Lynge J., Endahl L., et al. Albtullin-bolmd basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9 (2007) 290-299
26. Plank J., Bodenlenz M., and Sinner E. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005) 1107-1112
27. Danne T., Lupke K., Walte K., et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 26 (2003) 3087-3092
28. Hompesch M., Troupin B., Heise T., et al. Time-action profile of insulin detemir and NPtt insulin in patients with Vpe 2 diabetes from different ethnic groups. Diabetes Obes Metab 8 (2006) 568-573
29. Jhee S., Lyness W., Rojas P., et al. Similaxity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects. J Clin Pharmacol 44 (2004) 258-264
30. Hordern S., Wright J., and Umpleby A. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 48 (2005) 420-426
31. Hermansen K., Fontaine R., Kukolja K., et al. Insulin analogues Insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regtflax human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
32. Home P., Bartley R., Russell-Jones D., et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
33. Pieber T., Draeger E., Kristensen A., and Grill V. Comparison d three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 22 (2005) 850-857
34. Pieber T., Treichel H.-C., Robertson L., et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaema than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetologia 48 (2005) A92 Abstract
35. Roberts A., Standl E., Bayer T., et al. Efficacy and safety of 6-month treatmem with insulin detemir in type 1 diabetic patients on a basal-bolus regimen. Diabetologia 44 Suppl 1 (2001) A207 Abstract.
36. Robertson K., Schoenle E., Gucev Z., et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 24 (2007) 27-34
37. Russell-Jones D., Simpson R., Hylleberg B., et al. Effects of QD insulin detemir or neutrM protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26 (2004) 724-736
38. Vague R., Selam J.-L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-595
39. De Leeuw I., Vague R., Selam J.-L., et al. Insulin detemir used in basal-bolus therapy in people with Vpe 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7 (2005) 73-82
40. Standl E., Lung H., and Roberts A. The 12-month efficacy and safety of insulin detemir and NPII insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6 (2004) 579-588
41. Kølendorf K., Ross G., Pavlic-Renar I., et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 23 (2006) 729-735
42. Haak T., Tiengo A., and Draeger E. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7 (2005) 56-64
43. Rašlová K., Bogoev M., Raz I., et al. Corrigendum to "Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes". [DiabeIes Res Clin Pract 2004;66:193-201]. Diabetes Res Clin Pract 72 (2006) 112
44. Rašlová K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: a promising basM-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66 (2004) 193-201
45. Hermansen K., M D., Derezinski T., et al. A 26-week, randomized, parallel, tLeat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
46. Philis-Tsimikas A., G C., P C., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28 (2006) 1569-1581
47. Rosenstock J., Davies M., Home P., et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 55 (2006) A132 (Suppl) Abstract
48. Meneghini L., Rosenberg K., Koenen C., et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabexes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 9 (2007) 418-427
49. Valentine W., Palmer A., Erny-Albrecht K., et al. Cost-effectiveness of basal insulin from a [iS health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 23 (2006) 191-207
50. Palmer A., Roze S., Valentine W., et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an econoiNc analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 20 (2004) 1729-1746